News

The American Gastroenterological Association applauded the Supreme Court's Kennedy v. Braidwood decision, which preserves ...
Background: Non-alcoholic-steatohepatitis (NASH) leading to fibrosis, end-stage cirrhosis and hepatocellular carcinoma is an increasing health problem in the Western world. Thus, the need for new ...
† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ-glutamyltranspeptidase, ALT, AST and total ...
By Association of Language Companies The Association of Language Companies (ALC) is a U.S.-based international trade association, representing businesses that provide language services to any type of ...
Liver Int. 2012;32:911-8. 12 Gallego-durán R, Cerro-Salido P, Gomez-Gonzalez E, Pareja MJ, Ampuero J, Rico MC, et al. Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic ...
One of Japan’s “largest spirits companies” is in talks to buy a stake in Arkay Beverages, the non-alc spirits firm has said – although Suntory Holdings has denied it is involved in the negotiations.
Reviewer #3 (Public review): Summary: Mitochondrial oxphos causes lipid accumulation, leading to MASH, although the mechanism has been poorly understood. In this study, Funai and colleagues identify ...
In non-hepatocytes, low CL levels have been linked to electron leak in the context of a deficiency of the tafazzin gene, a CL transacylase, whose mutation promotes Barth syndrome. 15, 26, 59, 60 ...
June 12 (UPI) -- The U.N. nuclear energy watchdog ruled Thursday that Iran was in breach of its Nuclear Non-Proliferation Treaty obligations by failing to come clean about undeclared nuclear ...
The U.S. Food and Drug Administration had approved Ibtrozi (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The efficacy of the ...
After adjusting for demographic and metabolic factors, non-alcoholic steatohepatitis remained associated with adenomas (adjusted OR 4.89, 95% CI 2.04 to 11.70) and advanced neoplasms (OR 5.34, 95% CI ...